Works by Cheng-Yuan Peng


Results: 107
    1
    2

    Long-Term Hepatic and Extrahepatic Outcomes of Chronic Hepatitis C Patients After Sofosbuvir-Based Treatment (LONGHEAD Study).

    Published in:
    Infectious Diseases & Therapy, 2025, v. 14, n. 5, p. 1089, doi. 10.1007/s40121-025-01145-y
    By:
    • Huang, Chung-Feng;
    • Heo, Jeong;
    • Chien, Rong-Nan;
    • Baek, Yang-Hyun;
    • Kao, Jia-Horng;
    • Kim, Ju-Hyun;
    • Chang, Ting-Tsung;
    • Byun, Kwan-Soo;
    • Chen, Jyh-Jou;
    • Jeong, Sook-Hyang;
    • Hu, Tsung-Hui;
    • Kim, Young-Seok;
    • Peng, Cheng-Yuan;
    • Tak, Won-Young;
    • Wang, Horng-Yuan;
    • Yoon, Seung-Kew;
    • Sheen, I.-Shyan;
    • Youn-Jae Lee;
    • Hsu, Yu-Chun;
    • Yim, Hyung-Joon
    Publication type:
    Article
    3
    4
    5
    6
    7
    8
    9
    10
    11

    Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy.

    Published in:
    2020
    By:
    • Yang, Hwai-I;
    • Yeh, Ming-Lun;
    • Wong, Grace L;
    • Peng, Cheng-Yuan;
    • Chen, Chien-Hung;
    • Trinh, Huy N;
    • Cheung, Ka-Shing;
    • Xie, Qing;
    • Su, Tung-Hung;
    • Kozuka, Ritsuzo;
    • Lee, Dong-Hyun;
    • Ogawa, Eiichi;
    • Zhao, Changqing;
    • Ning, Hui-Bin;
    • Huang, Rui;
    • Li, Jiayi;
    • Zhang, Jian Q;
    • Ide, Tatsuya;
    • Xing, Huichun;
    • Iwane, Shinji
    Publication type:
    journal article
    12
    13

    An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions.

    Published in:
    2019
    By:
    • Huang, Chung-Feng;
    • Hung, Chao-Hung;
    • Cheng, Pin-Nan;
    • Bair, Ming-Jong;
    • Huang, Yi-Hsiang;
    • Kao, Jia-Horng;
    • Hsu, Shih-Jer;
    • Lee, Pei-Lun;
    • Chen, Jyh-Jou;
    • Chien, Rong-Nan;
    • Peng, Cheng-Yuan;
    • Lin, Chun-Yen;
    • Hsieh, Tsai-Yuan;
    • Cheng, Chun-Han;
    • Dai, Chia-Yen;
    • Huang, Jee-Fu;
    • Chuang, Wan-Long;
    • Yu, Ming-Lung
    Publication type:
    journal article
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23

    Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy.

    Published in:
    Liver Cancer (2235-1795), 2020, v. 9, n. 2, p. 207, doi. 10.1159/000504650
    By:
    • Tseng, Tai-Chung;
    • Peng, Cheng-Yuan;
    • Hsu, Yao-Chun;
    • Su, Tung-Hung;
    • Wang, Chia-Chi;
    • Liu, Chun-Jen;
    • Yang, Hung-Chih;
    • Yang, Wan-Ting;
    • Lin, Chia-Hsin;
    • Yu, Ming-Lung;
    • Lai, Hsueh-Chou;
    • Tanaka, Yasuhito;
    • Nguyen, Mindie H.;
    • Liu, Chen-Hua;
    • Chen, Pei-Jer;
    • Chen, Ding-Shinn;
    • Kao, Jia-Horng
    Publication type:
    Article
    24
    25
    26
    27
    28
    29
    30
    31

    Factors associated with treatment failure of direct‐acting antivirals for chronic hepatitis C: A real‐world nationwide hepatitis C virus registry programme in Taiwan.

    Published in:
    Liver International, 2021, v. 41, n. 6, p. 1265, doi. 10.1111/liv.14849
    By:
    • Chen, Chi‐Yi;
    • Huang, Chung‐Feng;
    • Cheng, Pin‐Nan;
    • Tseng, Kuo‐Chih;
    • Lo, Ching‐Chu;
    • Kuo, Hsing‐Tao;
    • Huang, Yi‐Hsiang;
    • Tai, Chi‐Ming;
    • Peng, Cheng‐Yuan;
    • Bair, Ming‐Jong;
    • Chen, Chien‐Hung;
    • Yeh, Ming‐Lun;
    • Lin, Chih‐Lang;
    • Lin, Chun‐Yen;
    • Lee, Pei‐Lun;
    • Chong, Lee‐Won;
    • Hung, Chao‐Hung;
    • Huang, Jee‐Fu;
    • Yang, Chi‐Chieh;
    • Hu, Jui‐Ting
    Publication type:
    Article
    32
    33

    Long‐term follow‐up of clinical trial patients treated for chronic HCV infection with daclatasvir‐based regimens.

    Published in:
    Liver International, 2018, v. 38, n. 5, p. 821, doi. 10.1111/liv.13596
    By:
    • Reddy, K. Rajender;
    • Pol, Stanislas;
    • Thuluvath, Paul J.;
    • Kumada, Hiromitsu;
    • Toyota, Joji;
    • Chayama, Kazuaki;
    • Levin, James;
    • Lawitz, Eric J.;
    • Gadano, Adrian;
    • Ghesquiere, Wayne;
    • Gerken, Guido;
    • Brunetto, Maurizia R.;
    • Peng, Cheng‐yuan;
    • Silva, Marcelo;
    • Strasser, Simone I.;
    • Heo, Jeong;
    • Mcphee, Fiona;
    • Liu, Zhaohui;
    • Yang, Rong;
    • Linaberry, Misti
    Publication type:
    Article
    34
    35

    Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.

    Published in:
    Liver International, 2016, v. 36, n. 12, p. 1755, doi. 10.1111/liv.13253
    By:
    • Su, Tung ‐ Hung;
    • Hu, Tsung ‐ Hui;
    • Chen, Chi ‐ Yi;
    • Huang, Yi ‐ Hsiang;
    • Chuang, Wan ‐ Long;
    • Lin, Chun ‐ Che;
    • Wang, Chia ‐ Chi;
    • Su, Wei ‐ Wen;
    • Chen, Ming ‐ Yao;
    • Peng, Cheng ‐ Yuan;
    • Chien, Rong ‐ Nan;
    • Huang, Yi ‐ Wen;
    • Wang, Horng ‐ Yuan;
    • Lin, Chih ‐ Lin;
    • Yang, Sheng ‐ Shun;
    • Chen, Tsung ‐ Ming;
    • Mo, Lein ‐ Ray;
    • Hsu, Shih ‐ Jer;
    • Tseng, Kuo ‐ Chih;
    • Hsieh, Tsai ‐ Yuan
    Publication type:
    Article
    36
    37

    A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection.

    Published in:
    Liver International, 2016, v. 36, n. 8, p. 1101, doi. 10.1111/liv.13082
    By:
    • Kao, Jia ‐ Horng;
    • Chien, Rong ‐ Nan;
    • Chang, Ting ‐ Tsung;
    • Peng, Cheng ‐ Yuan;
    • Hu, Tsung ‐ Hui;
    • Lo, Gin ‐ Ho;
    • Wang, Horng ‐ Yuan;
    • Chen, Jyh ‐ Jou;
    • Yang, Jenny C.;
    • Knox, Steven J.;
    • Han, Lingling;
    • Mo, Hongmei;
    • Mathias, Anita;
    • Brainard, Diana M.;
    • Sheen, I ‐ Shyan;
    • Hsu, Yu ‐ Chun;
    • Chu, Chi ‐ Jen;
    • Chuang, Wan ‐ Long
    Publication type:
    Article
    38

    Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis.

    Published in:
    Liver International, 2016, v. 36, n. 7, p. 954, doi. 10.1111/liv.13049
    By:
    • Kao, Jia ‐ Horng;
    • Jensen, Donald M.;
    • Manns, Michael P.;
    • Jacobson, Ira;
    • Kumada, Hiromitsu;
    • Toyota, Joji;
    • Heo, Jeong;
    • Yoffe, Boris;
    • Sievert, William;
    • Bessone, Fernando;
    • Peng, Cheng ‐ Yuan;
    • Roberts, Stuart K.;
    • Lee, Youn ‐ Jae;
    • Bhore, Rafia;
    • Mendez, Patricia;
    • Hughes, Eric;
    • Noviello, Stephanie
    Publication type:
    Article
    39
    40
    41
    42

    Hepatitis C Virus Reinfection in People With HIV in Taiwan After Achieving Sustained Virologic Response With Antiviral Treatment: The RECUR Study.

    Published in:
    Open Forum Infectious Diseases, 2022, v. 9, n. 8, p. 1, doi. 10.1093/ofid/ofac348
    By:
    • Liu, Chen-Hua;
    • Sun, Hsin-Yun;
    • Peng, Cheng-Yuan;
    • Hsieh, Szu-Min;
    • Yang, Sheng-Shun;
    • Kao, Wei-Yu;
    • Shih, Yu-Lueng;
    • Lin, Chih-Lin;
    • Liu, Chun-Jen;
    • Sheng, Wang-Hui;
    • Lo, Yi-Chun;
    • Liu, Wen-Chun;
    • Wu, Jo-Hsuan;
    • Su, Tung-Hung;
    • Tseng, Tai-Chung;
    • Chen, Pei-Jer;
    • Hung, Chien-Ching;
    • Kao, Jia-Horng
    Publication type:
    Article
    43
    44
    45
    46

    Real-World Efficacy and Safety of Universal 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve Patients from a Nationwide HCV Registry in Taiwan.

    Published in:
    Infectious Diseases & Therapy, 2024, v. 13, n. 6, p. 1199, doi. 10.1007/s40121-024-00968-5
    By:
    • Yang, Chun-Chi;
    • Huang, Chung-Feng;
    • Chang, Te-Sheng;
    • Lo, Ching-Chu;
    • Hung, Chao-Hung;
    • Huang, Chien-Wei;
    • Chong, Lee-Won;
    • Cheng, Pin-Nan;
    • Yeh, Ming-Lun;
    • Peng, Cheng-Yuan;
    • Cheng, Chien-Yu;
    • Huang, Jee-Fu;
    • Bair, Ming-Jong;
    • Lin, Chih-Lang;
    • Yang, Chi-Chieh;
    • Wang, Szu-Jen;
    • Hsieh, Tsai-Yuan;
    • Lee, Tzong-Hsi;
    • Lee, Pei-Lun;
    • Wu, Wen-Chih
    Publication type:
    Article
    47
    48
    49

    Real‐world efficacy and safety of universal 8‐week glecaprevir/pibrentasvir in patients with chronic hepatitis C with early chronic kidney disease or pre‐end‐stage renal disease: Insights from a nationwide hepatisis C virus registry in Taiwan

    Published in:
    Kaohsiung Journal of Medical Sciences, 2025, v. 41, n. 2, p. 1, doi. 10.1002/kjm2.12929
    By:
    • Wang, Szu‐Jen;
    • Huang, Chung‐Feng;
    • Chang, Te‐Sheng;
    • Lo, Ching‐Chu;
    • Hung, Chao‐Hung;
    • Huang, Chien‐Wei;
    • Chong, Lee‐Won;
    • Cheng, Pin‐Nan;
    • Yeh, Ming‐Lun;
    • Peng, Cheng‐Yuan;
    • Cheng, Chien‐Yu;
    • Huang, Jee‐Fu;
    • Bair, Ming‐Jong;
    • Lin, Chih‐Lang;
    • Yang, Chi‐Chieh;
    • Kuo, Hsing‐Tao;
    • Hsieh, Tsai‐Yuan;
    • Lee, Tzong‐Hsi;
    • Lee, Pei‐Lun;
    • Wu, Wen‐Chih
    Publication type:
    Article
    50

    Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan.

    Published in:
    Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-03006-3
    By:
    • Huang, Chung-Feng;
    • Kuo, Hsing-Tao;
    • Chang, Te-Sheng;
    • Lo, Ching-Chu;
    • Hung, Chao-Hung;
    • Huang, Chien-Wei;
    • Chong, Lee-Won;
    • Cheng, Pin-Nan;
    • Yeh, Ming-Lun;
    • Peng, Cheng-Yuan;
    • Cheng, Chien-Yu;
    • Huang, Jee-Fu;
    • Bair, Ming-Jong;
    • Lin, Chih-Lang;
    • Yang, Chi-Chieh;
    • Wang, Szu-Jen;
    • Hsieh, Tsai-Yuan;
    • Lee, Tzong-Hsi;
    • Lee, Pei-Lun;
    • Wu, Wen-Chih
    Publication type:
    Article